Clinical Trial Results:
A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving
concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.
Summary
|
|
EudraCT number |
2007-002964-90 |
Trial protocol |
BE FI FR HU ES NL EE AT SK DE GB CZ |
Global completion date |
29 Mar 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Aug 2023
|
First version publication date |
18 Aug 2023
|
Other versions |
|
Summary report(s) |
2007-002964-90 EudraCT Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.